Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells

Du,Hongchao; Zhou,Bin; Zhang,Hong; Jin,Yipeng; Zhang,Di; Lin,Degui

doi:10.3892/ol.2017.6164

Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells

Authors:
- Hongchao Du
- Bin Zhou
- Hong Zhang
- Yipeng Jin
- Di Zhang
- Degui Lin
View Affiliations

Affiliations: Department of Veterinary Clinical Science, College of Veterinary Medicine, China Agricultural University, Beijing 100193, P.R. China
Published online on: May 12, 2017 https://doi.org/10.3892/ol.2017.6164
Pages: 427-432

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Salinomycin (SAL), a polyether ionophore antibiotic, has been demonstrated to selectively kill cancer stem cells (CSCs) in various types of human tumor. The aim of the present study was to investigate the effects of SAL on canine mammary CSCs. CSCs in canine mammary carcinoma cell lines (CMT7364 and CIPp) were identified using a sphere formation assay and flow cytometry. The chemoresistance, invasive potential and expression of stem cell‑associated proteins of these spheres was then analyzed. This demonstrated that the spheres exhibited characteristics of CSCs, including a cluster of differentiation (CD)44+/CD24‑/low phenotype, upregulation of Wnt/β‑catenin signaling pathway‑associated proteins and chemoresistance. The viability of the spheres was decreased in a concentration‑ and time‑dependent manner following treatment with SAL, and the spheres did not exhibit increased resistance to SAL compared with their parental cells. In addition, exposure to SAL inhibited sphere‑formation and invasive potential in canine mammary CSCs in a dose‑dependent manner. Furthermore, SAL decreased the CD44+/CD24‑/low population and downregulated the expression of Wnt/β‑catenin signaling‑associated proteins (β‑catenin, Cyclin D1 and octamer‑binding transcription factor 4) in the spheres. In conclusion, the present study demonstrated that SAL is an effective inhibitor of canine mammary CSCs in vitro, indicating that SAL is a promising chemotherapeutic agent for the treatment of canine mammary carcinoma.

View Figures

View References

1	Vail DM and MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 18:781–792. 2000. View Article : Google Scholar : PubMed/NCBI
2	Sleeckx N, De Rooster H, Kroeze EJ Veldhuis, Van Ginneken C and Van Brantegem L: Canine mammary tumours, an overview. Reprod Domest Anim. 46:1112–1131. 2011. View Article : Google Scholar : PubMed/NCBI
3	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer Stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006. View Article : Google Scholar : PubMed/NCBI
4	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hu Y and Fu L: Targeting cancer stem cells: A new therapy to cure cancer patients. Am J Cancer Res. 2:340–356. 2012.PubMed/NCBI
6	Mitra A, Mishra L and Li S: EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10697–11711. 2015. View Article : Google Scholar : PubMed/NCBI
7	Im KS, Jang YG, Shin JI, Kim NH, Lim HY, Lee SM, Kim JH and Sur JH: CD44+/CD24- cancer stem cells are associated with higher grade of canine mammary carcinomas. Vet Pathol. 52:1041–1044. 2015. View Article : Google Scholar : PubMed/NCBI
8	Magalhães GM, Terra EM, de Oliveira Vasconcelos R, de Barros Bandarra M, Moreira PR, Rosolem MC and Alessi AC: Immunodetection of cells with a CD44+/CD24- phenotype in canine mammary neoplasms. BMC Vet Res. 9:2052013. View Article : Google Scholar : PubMed/NCBI
9	Michishita M, Akiyoshi R, Yoshimura H, Katsumoto T, Ichikawa H, Ohkusu-Tsukada K, Nakagawa T, Sasaki N and Takahashi K: Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines. Res Vet Sci. 91:254–260. 2011. View Article : Google Scholar : PubMed/NCBI
10	Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R and Martin AG: Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 31:1354–1365. 2012. View Article : Google Scholar : PubMed/NCBI
11	Oliveira LR, Jeffrey SS and Ribeiro-Silva A: Stem cells in human breast cancer. Histol Histopathol. 25:371–385. 2010.PubMed/NCBI
12	Michishita M, Akiyoshi R, Suemizu H, Nakagawa T, Sasaki N, Takemitsu H, Arai T and Takahashi K: Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J. 193:508–513. 2012. View Article : Google Scholar : PubMed/NCBI
13	Naujokat C and Steinhart R: Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012:9506582012. View Article : Google Scholar : PubMed/NCBI
14	Torres CG, Olivares A and Stoore C: Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells. Oncol Rep. 33:2235–2244. 2015.PubMed/NCBI
15	Pang LY, Cervantes-Arias A, Else RW and Argyle DJ: Canine mammary cancer stem cells are radio- and chemo- resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers (Basel). 3:1744–1762. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM and Wu E: Salinomycin: A novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem. 20:4095–4101. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E and Roidl A: Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 13:162014. View Article : Google Scholar : PubMed/NCBI
18	Lu D, Choi MY, Yu J, Castro JE, Kipps TJ and Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 108:pp. 13253–13257. 2011; View Article : Google Scholar : PubMed/NCBI
19	Lu W and Li Y: Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem. 115:1799–1807. 2014. View Article : Google Scholar : PubMed/NCBI
20	Uyama R, Nakagawa T, Hong SH, Mochizuki M, Nishimura R and Sasaki N: Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 4:104–113. 2006. View Article : Google Scholar : PubMed/NCBI
21	Dalerba P and Clarke MF: Cancer stem cells and tumor metastasis: First steps into uncharted territory. Cell Stem Cell. 1:241–242. 2007. View Article : Google Scholar : PubMed/NCBI
22	Li F, Tiede B, Massagué J and Kang Y: Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
23	Grange C, Lanzardo S, Cavallo F, Camussi G and Bussolati B: Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia. 10:1433–1443. 2008. View Article : Google Scholar : PubMed/NCBI
24	Simmons MJ, Serra R, Hermance N and Kelliher MA: NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res. 14:R1262012. View Article : Google Scholar : PubMed/NCBI
25	Ferletta M, Grawé J and Hellmén E: Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol. 55:791–799. 2011. View Article : Google Scholar : PubMed/NCBI
26	Huang J, Zhang D, Xie F and Lin D: The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: An immunohistochemical study. J Vet Sci. 16:225–231. 2015. View Article : Google Scholar : PubMed/NCBI
27	Curtin JC and Lorenzi MV: Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 1:552–566. 2010. View Article : Google Scholar : PubMed/NCBI
28	Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M and Liu C: Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res. 16:4082014. View Article : Google Scholar : PubMed/NCBI
29	Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T and Wang J: Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 311:113–121. 2011. View Article : Google Scholar : PubMed/NCBI
30	Mao J, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, et al: Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 5:e10392014. View Article : Google Scholar : PubMed/NCBI
31	Zhang X, Lou Y, Zheng X, Wang H, Sun J, Dong Q and Han B: Wnt blockers inhibit the proliferation of lung cancer stem cells. Drug Des Devel Ther. 9:2399–2407. 2015.PubMed/NCBI
32	Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, et al: Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 7:e506382012. View Article : Google Scholar : PubMed/NCBI
33	Qu H, Ma B, Yuan HF, Wang ZY, Guo SJ and Zhang J: Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 8:578–582. 2015. View Article : Google Scholar : PubMed/NCBI